To evaluate the incidence of adverse effects and perceived benefits of pharmacological therapy in pediatric patients with chronic non-cancer pain within the first month of treatment, highlighting the significance of understanding these factors in pediatric care.
Key Findings:
81% of patients reported adverse effects, totaling 572 events, indicating a significant concern for safety.
Most common adverse effects were gastrointestinal (62%) and attention-related (61%), which may impact treatment adherence.
Perceived benefits were reported by 77% of patients, with analgesic benefit being the most common (64%), suggesting that many patients experience positive outcomes.
The incidence of adverse effects increased with the number of concomitant medications, highlighting the risks associated with polypharmacy.
Interpretation:
Adverse effects are prevalent in the early stages of pharmacological treatment for pediatric chronic pain, particularly with polypharmacy, while patients also report significant perceived benefits, underscoring the need for careful monitoring.
Limitations:
Severity of adverse effects and causality were not assessed, which limits the understanding of the clinical significance of these findings.
The study does not establish drug-specific efficacy or interactions, and potential biases or confounding factors were not addressed.
Conclusion:
The findings highlight the need for safety monitoring and informed decision-making in pharmacological treatments for pediatric chronic pain, emphasizing the importance of ongoing research in this area.
